Women’s Health Bulletin

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Authorship Rules and Regulations

Indexing and Abstracting

Peer Review Process

Forms

Association between Treatment Adherence and Depression with Health- Related Quality of Life in Women with Vitiligo

Document Type : Research Article

Authors

Department of Psychology, Ahvaz Branch, Islamic Azad University, Ahvaz, Iran

10.30476/whb.2024.102120.1283

Abstract

Background: Vitiligo, a chronic depigmentary dermatosis, significantly compromises health-related quality of life (HRQoL), especially among women. Treatment adherence and depression are two important factors that can influence HRQoL in these patients. This study aimed to investigate the association between treatment adherence, depression, and HRQoL in women with vitiligo.
Methods: A cross-sectional study was conducted on 152 women with vitiligo who were selected using convenient sampling method from a dermatology clinic in Ahvaz, Iran, in 2023. The study employed the MOS 36-Item Short-Form Health Survey (SF-36), Treatment Adherence Questionnaire (TAQ), and Beck Depression Inventory (BDI) to collect data. Pearson correlation coefficients assessed the relationships between variables, while stepwise regression analysis explored the independent contributions of these factors to the outcome variables.
Results: Our results showed mean scores (SD) of 58.13 (11.50) for HRQoL, 49.70 (8.82) for treatment adherence, and 20.25 (4.47) for depression. Significant positive and negative correlations were observed between treatment adherence and HRQoL (r=0.44, P<0.001) and depression and HRQoL (r=-0.36, P<0.001), respectively. Furthermore, regression analysis confirmed that both treatment adherence (β=0.51, P<0.001) and depression (β=-0.57, P<0.001) were significantly associated with HRQoL in women with vitiligo.
Conclusion: These results highlighted the importance of treatment adherence as a key factor influencing HRQoL in women with vitiligo. Additionally, the study underscores the negative impact of depression on HRQoL, suggesting the potential benefit of addressing both treatment adherence and depression in clinical management strategies to optimize HRQoL for women with vitiligo.

Highlights

How to Cite: Noori M, Johari Fard R. Association between Treatment Adherence and Depression with Health-Related Quality of Life in Women with Vitiligo. Women. Health. Bull. 2024;11(2):128-134. doi: 10.30476/WHB.2024.102120.1283.

Keywords

References
  1. Chang WL, Lee WR, Kuo YC, Huang YH. Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention. Front Cell Dev Biol. 2021;9:797026. doi: 10.3389/fcell.2021.797026. PubMed PMID: 34970551; PubMed Central PMCID: PMC8712646. ##
  2. Ramawanshi SM, Chandela M, Manjegowda D, Kumar S, Potdar S. Assessment of Clinical VIDA Score, Lesional and Perilesional Dermoscopy to Evaluate Stability of the Disease in Vitiligo. Clinical Dermatology Review. 2024;8(1):26-30. doi: 10.4103/cdr.cdr_60_22. ##
  3. Joge RR, Kathane PU, Joshi SH. Vitiligo: A Narrative Review. Cureus. 2022;14(9):e29307. doi: 10.7759/cureus.29307. PubMed PMID: 36304341; PubMed Central PMCID: PMC9586189. ##
  4. Lerner AB. On the etiology of vitiligo and gray hair. The American Journal of Medicine. 1971;51(2):141-7. doi: 10.1016/0002-9343(71)90232-4. ##
  5. Bertolani M, Rodighiero E, de Felici Del Giudice MB, Lotti T, Feliciani C, et al. Vitiligo: What's old, what's new. Dermatol Reports. 2021;13(2):9142. doi: 10.4081/dr.2021.9142. PubMed PMID: 34659674; PubMed Central PMCID: PMC8451070. ##
  6. Al-smadi K, Imran M, Leite-Silva VR, Mohammed Y. Vitiligo: A Review of Aetiology, Pathogenesis, Treatment, and Psychosocial Impact. Cosmetics. 2023;10(3). doi: 10.3390/cosmetics10030084. ##
  7. Grimes PE, Miller MM. Vitiligo: Patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol. 2018;4(1):32-37. doi: 10.1016/j.ijwd.2017.11.005. PubMed PMID: 29872674; PubMed Central PMCID: PMC5986114. ##
  8. Salama AH, Alnemr L, Khan AR, Alfakeer H, Aleem Z, Ali-Alkhateeb M. Unveiling the Unseen Struggles: A Comprehensive Review of Vitiligo's Psychological, Social, and Quality of Life Impacts. Cureus. 2023;15(9):e45030. doi: 10.7759/cureus.45030. PubMed PMID: 37829995; PubMed Central PMCID: PMC10566310. ##
  9. Baidya S, Dey P, Mohanty R. Assessment of quality of life in vitiligo patients attending a tertiary care hospital - A cross sectional study. Ind Psychiatry J. 2021;30(1):62-66. doi: 10.4103/ipj.ipj_16_20. PubMed PMID: 34483526; PubMed Central PMCID: PMC8395564. ##
  10. Abdi K, Hosseini FB, Chaharbaghi Z, Ghorbani S. Impact of Social Support on Wellbeing and Health-Related Quality of Life among Elderly Women: Mediating Role of Physical Activity. Women Health Bull. 2022;9(2):104-109. doi: 10.30476/whb.2022.94981.1174. ##
  11. Defar S, Abraham Y, Reta Y, Deribe B, Jisso M, Yeheyis T, et al. Health related quality of life among people with mental illness: The role of socio-clinical characteristics and level of functional disability. Front Public Health. 2023;11:1134032. doi: 10.3389/fpubh.2023.1134032. PubMed PMID: 36875411; PubMed Central PMCID: PMC9978447. ##
  12. Mbada C, Ehinomen JO, Mbada KA, Akinwande OA, Adeyemi AB, Orji OE, et al. Body Image and Health-Related Quality of Life of Nigerian Nulligravid, Pregnant, and Postpartum Women. Women Health Bull. 2020;7(1):39-47. doi: 10.30476/whb.2020.85063.1038. ##
  13. Sayed Ali MA, Abou-Taleb DAE, Mohamed RR. Treatment adherence and beliefs about medicines among Egyptian vitiligo patients. Dermatol Ther. 2016;29(6):413-418. doi: 10.1111/dth.12397. PubMed PMID: 27594551. ##
  14. Hevey D. Adherence to Health Recommendations. In: Perk J, Gohlke H, Hellemans I, Sellier P, Mathes P, Monpère C, et al., editors. Cardiovascular Prevention and Rehabilitation. London: Springer London; 2007. p. 293-300. ##
  15. Fernandez-Lazaro CI, García-González JM, Adams DP, Fernandez-Lazaro D, Mielgo-Ayuso J, Caballero-Garcia A, et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract. 2019;20(1):132. doi: 10.1186/s12875-019-1019-3. PubMed PMID: 31521114; PubMed Central PMCID: PMC6744672. ##
  16. Chen F, Bailey CE, Alvarez RD, Shu XO, Zheng W. Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer. Gynecol Oncol. 2021;160(1):10-15. doi: 10.1016/j.ygyno.2020.10.040. PubMed PMID: 33208254. ##
  17. Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F. Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population. Health Qual Life Outcomes. 2020;18(1):20. doi: 10.1186/s12955-020-1278-7. PubMed PMID: 32013982; PubMed Central PMCID: PMC6998062. ##
  18. Pourfereydoun MH, Dasht Bozorgi Z. Effectiveness of Cognitive Rehabilitation Therapy on Psychological Distress and Self-Compassion in Mastectomized Women with Depression. Women Health Bull. 2023;10(2):87-95. doi: 10.30476/whb.2023.97735.1219. ##
  19. Kupferberg A, Hasler G. The social cost of depression: Investigating the impact of impaired social emotion regulation, social cognition, and interpersonal behavior on social functioning. Journal of Affective Disorders Reports. 2023;14:100631. doi: 10.1016/j.jadr.2023.100631. ##
  20. Buyukdura JS, McClintock SM, Croarkin PE. Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):395-409. doi: 10.1016/j.pnpbp.2010.10.019. PubMed PMID: 21044654; PubMed Central PMCID: PMC3646325. ##
  21. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023;401(10371):141-153. doi: 10.1016/S0140-6736(22)02080-3. PubMed PMID: 36535295. ##
  22. Tröger A, Miguel C, Ciharova M, de Ponti N, Durman G, Cuijpers P, et al. Baseline depression severity as moderator on depression outcomes in psychotherapy and pharmacotherapy. J Affect Disord. 2024;344:86-99. doi: 10.1016/j.jad.2023.10.047. PubMed PMID: 37820960. ##
  23. Maxwell SE. Sample size and multiple regression analysis. Psychol Methods. 2000;5(4):434-58. doi: 10.1037/1082-989x.5.4.434. PubMed PMID: 11194207. ##
  24. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83. PubMed PMID: 1593914. ##
  25. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005;14(3):875-82. doi: 10.1007/s11136-004-1014-5. PubMed PMID: 16022079. ##
  26. Seyed Fatemi N, Rafii F, Hajizadeh E, Modanloo M. Psychometric properties of the adherence questionnaire in patients with chronic disease: A mix method study. Koomesh. 2018;20(2):179-191. Persian. ##
  27. Beck A, Steer R, Brown G. Beck Depression Inventory. 2nd San Antonio, TX, E.U.: Psychological Corporation; 1996. ##
  28. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. Depress Anxiety. 2005;21(4):185-92. doi: 10.1002/da.20070. PubMed PMID: 16075452. ##
  29. Sakkaki S, Naderi F, Hafezi F. Relationships Between Chronic Fatigue Syndrome, Experiential Avoidance, and Health-Related Quality of Life in Cervical Cancer Cases Mediated by Depression. Women Health Bull. 2023;10(2):104-111. doi: 10.30476/whb.2023.98545.1228. ##
  30. Onu DU. Treatment adherence mediates the relationship between HIV-related stigma and health-related quality of life. AIDS Care. 2021;33(10):1335-1339. doi: 10.1080/09540121.2020.1867701. PubMed PMID: 33427481. ##
  31. Samalin L, Yrondi A, Charpeaud T, Genty JB, Blanc O, Sauvaget A, et al. Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode. J Affect Disord. 2020;264:318-323. doi: 10.1016/j.jad.2020.01.004. PubMed PMID: 32056767. ##
  32. Skandari H, Gatezadeh A, Borjali A, Sohrabi F. Explanation of Depression on Lifestyle through the Mediation of Social Health and Quality of Life in adults of Ahvaz. Counseling Culture and Psycotherapy. 2017;8(31):1-21. doi: 10.22054/qccpc.2017.16989.1394. ##
  33. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. doi: 10.1016/j.bcp.2020.114147. PubMed PMID: 32653589; PubMed Central PMCID: PMC7347500. ##
  34. Hays RD, Fayers PM. Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures. Pharmacoeconomics. 2021;39(6):627-630. doi: 10.1007/s40273-020-00972-w. PubMed PMID: 33135149; PubMed Central PMCID: PMC8088445. ##
Women’s Health Bulletin
Volume 11, Issue 2 - Serial Number 42
April 2024
Pages 128-134
Files
Share
How to cite
Statistics